利沃多巴与利沃多巴在早期帕金森病中的节约:我们可以在半路上相遇吗?
Mayela Rodríguez-Violante1,2, Ana J Hernández-Medrano1, Amin Cervantes-Arriaga1
1Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
概括
对于早期的帕金森病,本综述将利沃多巴与利沃多巴节约治疗进行比较. 它评估好处和缺点,以指导初始治疗选择,以获得最佳的患者结果.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 单疗法是早期帕金森病 (PD) 的标准.
- 最初的药理选择包括多巴胺激素激应剂,单胺氧化酶B抑制剂和乐伏多巴配方.
- 治疗选择取决于疾病的严重程度,持续时间,患者年龄,活动和并发症风险.
研究的目的:
- 综合评估有关levodopa与levodopa节约策略的文献.
- 评估这些方法在未使用药物的早期PD患者中的好处和缺点.
主要方法:
- 系统的文献审查.
- 对治疗疗效和副作用的现有证据的分析.
- 评估历史治疗趋势及其后果.
主要成果:
- 历史上的利沃多巴厌恶 (1990年代末-2000年代初) 由于动力障碍的担忧.
- 转向多巴胺激动剂导致了冲动控制障碍的增加.
- 随后的多巴胺激动剂厌恶 (2000年代中期) 强调了治疗的复杂性.
结论:
- 在levodopa和levodopa节约剂之间做出选择需要仔细考虑疗效和副作用的概况.
- 了解过去的治疗转变,可以为早期PD的当前临床决策提供信息.
- 需要进一步的研究来优化对帕金森病的初始单疗法.
相关概念视频
01:24Parkinson's Disease: Treatment
244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
01:15Parkinson's Disease: Overview
517
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
517
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:28Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172